We are live on
!
Find out more
BioMarin Pharmaceuticals
BMRN
BMRN
306 hedge funds and large institutions have $9.95B invested in BioMarin Pharmaceuticals in 2013 Q4 according to their latest regulatory filings, with 51 funds opening new positions, 101 increasing their positions, 115 reducing their positions, and 39 closing their positions.
New
Increased
Maintained
Reduced
Closed
63% more call options, than puts
Call options by funds: $94.9M | Put options by funds: $58.2M
31% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 39
4% more funds holding
Funds holding: 294 → 306 (+12)
2% less capital invested
Capital invested by funds: $10.1B → $9.95B (-$167M)
12% less repeat investments, than reductions
Existing positions increased: 101 | Existing positions reduced: 115
22% less funds holding in top 10
Funds holding in top 10: 9 → 7 (-2)
Holders
306
Holders Change
+12
Holders Change %
+4.08%
% of All Funds
8.88%
Holding in Top 10
7
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-22.22%
% of All Funds
0.2%
New
51
Increased
101
Reduced
115
Closed
39
Calls
$94.9M
Puts
$58.2M
Net Calls
+$36.7M
Net Calls Change
+$3.33M
Top Buyers
| 1 |
Wells Fargo
San Francisco,
California
|
+$97.2M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$78.6M |
| 3 |
Alkeon Capital Management
New York
|
+$68M |
| 4 |
Millennium Management
New York
|
+$60.7M |
| 5 |
State Street
Boston,
Massachusetts
|
+$50M |
Top Sellers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$265M |
| 2 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$40.1M |
| 3 |
Goldman Sachs
New York
|
-$39.5M |
| 4 |
D.E. Shaw & Co
New York
|
-$38.4M |
| 5 |
ACPU
Arrowgrass Capital Partners (US)
Dover,
Delaware
|
-$34.4M |
